Research Center for Biopharmaceutical Innovation and Technology
Research Center for Biopharmaceutical Innovation and Technology
Research Center for Biopharmaceutical Innovation and Technology peptide/protein/antibody/cell-based biopharmaceutical candidates. and delivery source technology research, gene-based cancer, infectious disease, metabolic/inflammatory/immune disease diagnosis/prevention/treatment nanotechnology, cell therapy and We are performing source technology related to regenerative medicine.
Staff organizational chart
DirectorJun Dae-won
Brief history
Department of Gastroenterology, College of Medicine
(Concurrent) Professor, Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University
(Concurrent) Professor, Department of Medical and Digital Engineering, College of Engineering
Research topics
Research on peptide / protein / antibody / cell-based biopharmaceutical candidates and original technology for drug delivery
Nanotechnology for gene-based diagnosis/prevention/treatment of cancers, infectious diseases, metabolic/inflammatory/immune diseases
Original technology related to cell therapy and regenerative medicine
Development of new drug screening platform based on bio–big data
Research on peptide/protein/antibody/cell-based biopharmaceutical candidates and delivery-related original technology
Nanotechnology for gene-based cancer, infectious disease, metabolic/inflammatory/immune disease diagnosis/prevention/treatment
Original technology related to cell therapy and regenerative medicine
Synthetic drug development
Daegu Cheombok Complex, Ewha Womans University College of Pharmacy and regular meeting related to synthetic new drugs (once a month)
Application for patent for Daegu Cheombokdanji No. 1 synthetic new drug
Concluded a confidentiality agreement with Theragen Bio to discuss out-licensing of related new drugs
Future Medicine first in class drug phase 2a domestic multi-center clinical study commissioned
After J2H first in class drug phase 1 was completed, a domestic multi-center clinical phase 2 study was requested.
Biotoxtech Korea's first commercial primate center establishment related business agreement and promotion of joint work for establishment of primate model
RNA-based New Drug Development Team
Started research meeting for RNA-based new drug development for 2 targets
New drug development team based on digital therapy
Completion of work cooperation and division of work for the development of Gaji Lab and digital therapeutics
Digital therapeutics-based clinical research from November 2022
2023. 2. 6. Signed MOU with Gaji Lab for the development of digital therapeutics